1,4-二恶烷-2-甲胺盐酸盐 | 1185156-19-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 中文名称: 1,4-二恶烷-2-甲胺盐酸盐
• 英文名称: (1,4-dioxan-2-yl)methylamine hydrochloride
• 英文别名: (1,4-Dioxan-2-yl)methanamine hydrochloride；1,4-dioxan-2-ylmethanamine;hydrochloride
• CAS: 1185156-19-7
• 化学式: C₅H₁₁NO₂*ClH
• mdl: MFCD06739050
• 分子量: 153.609
• InChiKey: LPQNAKGJOGYMDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.83
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  44.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-{[1-(4-chlorobenzoyl)piperidin-4-yl]methyl}-4-methyl-2H-indazol-5-carboxylic acid 、 1,4-二恶烷-2-甲胺盐酸盐 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二甲基亚砜 为溶剂， 反应 1.0h， 以185 mg的产率得到(+/-)-2-{[1-(4-chlorobenzoyl)piperidin-4-yl]methyl}-N-((1,4-dioxan-2-yl)methyl)-4-methyl-2H-indazole-5-carboxamide
  参考文献：
  名称：

  PHARMACEUTICAL COMPOSITION AND THE USE THEREOF, AND APPLICATION REGIME OF SAID PHARMACEUTICAL COMPOSITION FOR ON-DEMAND CONTRACEPTION

  摘要：

  这项发明涉及一种用于非激素、按需避孕的药物组合物，以及制备该药物组合物的方法。后者包括2H-吲哚唑作为新型EP2受体拮抗剂，与COX抑制剂结合使用。该发明还提供了一种非激素女性控制的按需避孕方法，其中在预期性交前按需服用含有EP2受体拮抗剂与COX抑制剂的药物组合物。

  公开号：

  US20160089364A1

文献信息

• [EN] 5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE AND 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE DERIVATIVES AS C-MYC AND P300/CBP HISTONE ACETYLTRANSFERASE INHIBITORS FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE 5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE ET DE 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE UTILISÉS EN TANT QU'INHIBITEURS D'HISTONE ACÉTYLTRANSFÉRASE DE C-MYC ET P300/CBP POUR LE TRAITEMENT DU CANCER
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019049061A1

  公开（公告）日：2019-03-14

  The invention is directed to substituted 5-(1H-benzo[d]imidazo-2-yl)- pyridin-2-amine and 5-(3H-imidazo[4,5-b]pyridin-6-yl)-pyridin-2-amine derivatives. Specifically, the invention is directed to compounds according to Formula (lb) wherein R', R2', R3', R4', Rs', R6', R7', and X1' are as defined herein; or a salt thereof including a pharmaceutically acceptable salt thereof. The compounds of the invention decrease MYC protein (c-MYC) in cells and/or inhibit p300/CBP histone acetyltransferase and can be useful in the treatment of cardiac hypertrophy, diabetes, obesity & nonalcoholic fatty liver disease, HIV, polycystic kidney disease, inflammatory diseases, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, multiple sclerosis, cancer and pre-cancerous syndromes, and diseases associated with dysregulation of Myc or inhibition of p300/CBP histone acetyltransferase. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention still further discloses methods of reducing MYC protein (c-MYC) in cells and inhibiting p300/CBP histone acetyltransferase activity, and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代的5-(1H-苯并[d]咪唑-2-基)-吡啶-2-胺和5-(3H-咪唑[4,5-b]吡啶-6-基)-吡啶-2-胺衍生物。具体而言，本发明涉及根据公式(lb)的化合物，其中R'、R2'、R3'、R4'、Rs'、R6'、R7'和X1'按本说明书中定义；或其盐，包括药用可接受的盐。本发明的化合物能够降低细胞中的MYC蛋白（c-MYC）和/或抑制p300/CBP组蛋白乙酰转移酶，可用于治疗心肌肥大、糖尿病、肥胖和非酒精性脂肪肝疾病、HIV、多囊肾疾病、炎症性疾病、强直性脊柱炎、银屑病、银屑病关节炎、类风湿性关节炎、克罗恩病、多发性硬化症、癌症和前癌症综合症，以及与Myc失调或p300/CBP组蛋白乙酰转移酶抑制相关的疾病。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步公开了使用本发明的化合物或包含本发明化合物的药物组合物，降低细胞中MYC蛋白（c-MYC）和抑制p300/CBP组蛋白乙酰转移酶活性的方法，以及治疗与之相关的疾病的方法。
• [EN] NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR<br/>[FR] FORMULATION DE NANOPARTICULES D'INHIBITEUR DE LA BCL-2
  申请人：RECURIUM IP HOLDINGS LLC

  公开号：WO2021007303A1

  公开（公告）日：2021-01-14

  Various albumin nanoparticle Bcl-2 inhibitor formulations are described, along with methods of using them to treat conditions characterized by excessive cellular proliferation, such as cancer and tumors. In various embodiments, such Bcl-2 inhibitor formulations contain albumin and a compound of the following Formula (I), or a pharmaceutically acceptable salt thereof, where the variables in Formula (I) are defined herein.

  描述了各种白蛋白纳米颗粒Bcl-2抑制剂配方，以及使用它们治疗由细胞过度增殖所表征的疾病的方法，例如癌症和肿瘤。在各种实施例中，这种Bcl-2抑制剂配方包含白蛋白和以下化合物的化合物（I）或其药用可接受的盐，其中化合物（I）中的变量在此处定义。
• SUBSTITUENT-INCLUDING UREA COMPOUND
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3915558A1

  公开（公告）日：2021-12-01

  An object of the present invention is to provide a compound that has a specific chemical structure having an activation effect on SIRT6 and is useful as an active component for preventing and treating inflammatory diseases. The present invention relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. (Each symbol in Formula (1) has the same definition as that described in the specification.)

  本发明的目的是提供一种化合物，该化合物具有特定的化学结构，对 SIRT6 具有激活作用，可作为预防和治疗炎症性疾病的活性成分。本发明涉及一种由式（1）代表的化合物或其药学上可接受的盐。 式（1）中各符号的定义与说明书中所述的相同）。
• MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
  申请人：AbbVie Inc.

  公开号：EP3988555A1

  公开（公告）日：2022-04-27

  The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

  本公开提供了式 (I) 的化合物 其中 A2、A3、A4、A6、A7、A8、A15、RA、R5、R9、R10A、R10B、R11、R12、R13、R14、R16、W、X 和 Y 具有说明书中定义的任一值，及其药学上可接受的盐，可用作治疗疾病和病症（包括癌症）的药物。还提供了包含式（I）化合物的药物组合物。
• Macrocyclic MCL-1 inhibitors and methods of use
  申请人：AbbVie Inc.

  公开号：US10676485B2

  公开（公告）日：2020-06-09

  The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

  本公开提供了式 (I) 的化合物 其中 A2、A3、A4、A6、A7、A8、A15、RA、R5、R9、R10A、R10B、R11、R12、R13、R14、R16、W、X 和 Y 具有说明书中定义的任一值，及其药学上可接受的盐，可用作治疗疾病和病症（包括癌症）的药物。还提供了包含式（I）化合物的药物组合物。